The Hepatobiliary System Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatobiliary System Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatobiliary System Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatobiliary System Tumor and features dormant and discontinued products.
GlobalData tracks six drugs in development for Hepatobiliary System Tumor by six companies/universities/institutes. The top development phase for Hepatobiliary System Tumor is phase ii with four drugs in that stage. The Hepatobiliary System Tumor pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hepatobiliary System Tumor pipeline products market are: Merck, Rigel Pharmaceuticals and Exelixis.
The key targets in the Hepatobiliary System Tumor pipeline products market include Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1), BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1), and Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1).
The key mechanisms of action in the Hepatobiliary System Tumor pipeline product include Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Ra with one drug in Phase II. The Hepatobiliary System Tumor pipeline products include three routes of administration with the top ROA being Oral and three key molecule types in the Hepatobiliary System Tumor pipeline products market including Small Molecule, and Biologic.
Hepatobiliary System Tumor overview
A tumor in the hepatobiliary system is a disorder that affects the normal function of the system. The hepatobiliary system includes the liver, gallbladder, and bile ducts
For a complete picture of Hepatobiliary System Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
